Wall Street Zen Upgrades Jasper Therapeutics (NASDAQ:JSPR) to Hold

Jasper Therapeutics (NASDAQ:JSPR) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

JSPR has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Friday, July 17th. Piper Sandler began coverage on shares of Jasper Therapeutics in a report on Wednesday, August 12th. They issued an “overweight” rating and a $2.00 price objective on the stock. William Blair initiated coverage on shares of Jasper Therapeutics in a report on Wednesday, October 14th. They issued an “outperform” rating on the stock. Finally, HC Wainwright reissued a “buy” rating on shares of Jasper Therapeutics in a report on Tuesday, August 18th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $7.33.

Jasper Therapeutics Price Performance

NASDAQ:JSPR opened at $0.52 on Friday. Jasper Therapeutics has a 1 year low of $0.32 and a 1 year high of $2.42. The company has a market cap of $17.31 million, a P/E ratio of -0.33 and a beta of 3.30. The stock’s fifty day moving average price is $0.60 and its two-hundred day moving average price is $0.86.

Jasper Therapeutics (NASDAQ:JSPR) last issued its earnings results on Friday, August 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.17. On average, analysts expect that Jasper Therapeutics will post -0.94 earnings per share for the current fiscal year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ:JSPR) is a clinical-stage biotechnology company focused on developing therapies that target c-Kit (CD117), a protein found on hematopoietic stem cells and mast cells. The company is pursuing treatments intended to address diseases involving abnormal immune or blood-cell activity, as well as approaches that may improve preparation for hematopoietic stem-cell transplantation.

Jasper’s lead investigational product is briquilimab, formerly known as JSP191. Briquilimab is an anti-CD117 monoclonal antibody designed to deplete certain stem cells and mast cells.